Close Menu

Myriad

Myriad Genetics' shareholders of record on June 17 will receive on June 30 a pro-rata dividend of .25 share of Myriad Pharmaceuticals common stock for each share of Myriad Genetics held.

The two-for-one split of the firm's shares took place before the opening of the market today.

The partners are deciding whether to run the multiplex test on a microarray or a sequencing platform. Factors in the decision include the complexity of the test and the technical feasibility of multiplexed, targeted resequencing.

The firm's two-for-one stock split will cut the number of shares it will distribute to current shareholders in Myriad Pharmaceuticals.

On its website, the company informs customers that its service tests for the i4000377, i4000378, and i4000379 SNPs in BRCA1 and BRCA2 genes, either one of which may “influence your carrier status for breast/ovarian cancer.”

Pages

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.